OptimizeRx Corp. (NASDAQ: OPRX) Sees Positive Outlook from Roth Capital with "Buy" Rating

• Roth Capital upgrades OptimizeRx Corp. (NASDAQ: OPRX) to a "Buy" rating and raises the price target from $22 to $27.
• The company reports earnings of $0.24 per share for Q2, a 700% earnings surprise, significantly beating the Zacks Consensus Estimate.
• OptimizeRx's Q2 revenues reached $29.2 million, a 55% increase year-over-year, with the company also improving its fiscal year 2025 guidance.

OptimizeRx Corp. (NASDAQ: OPRX) is a key player in the healthcare technology sector, providing solutions that help life sciences companies engage with healthcare professionals and patients. On August 7, 2025, Roth Capital upgraded OPRX to a "Buy" rating, with the stock priced at $12.84. Roth Capital also raised the price target from $22 to $27, indicating confidence in the company's future performance.

OptimizeRx's recent financial results support this optimistic outlook. The company reported earnings of $0.24 per share for the second quarter, significantly surpassing the Zacks Consensus Estimate of $0.03 per share. This represents a 700% earnings surprise and a substantial improvement from the $0.02 per share reported in the same quarter last year. Such strong earnings performance highlights OptimizeRx's ability to exceed market expectations.

In addition to impressive earnings, OptimizeRx reported revenues of $29.2 million for the quarter ending in June 2025. This figure exceeded the Zacks Consensus Estimate by 30.51% and marked a 55% increase from the $18.81 million reported a year ago. The company's consistent ability to surpass consensus estimates over the past four quarters underscores its robust financial health and growth trajectory.

OptimizeRx's strategic financial decisions further bolster its market position. The company paid down $4.5 million of principal on its outstanding term loan during the second quarter, demonstrating prudent financial management. Additionally, OptimizeRx updated its fiscal year 2025 guidance, projecting revenues between $104 million and $108 million, with adjusted EBITDA expected to range from $14.5 million to $17.5 million.

The stock's recent performance reflects these positive developments. Trading at $12.84, OPRX has seen a 2.88% price increase, with fluctuations between $12.12 and $13.13 during the day. Over the past year, the stock has reached a high of $15.71 and a low of $3.78, with a market capitalization of approximately $237.48 million. This performance, coupled with strong financial results, positions OptimizeRx for continued growth in the healthcare technology sector.